Navigation Links
DePuy ASR Hip Replacement Lawsuits: Bernstein Liebhard LLP Notes Upcoming Conference in New Jersey DePuy ASR Hip Recall Litigation
Date:4/28/2013

all, the U.S. Food & Drug Administration (FDA) launched a safety review of metal-on-metal hip implants. In January, the agency proposed a new rule that would make all-metal hips ineligible for the agency’s 510(k) clearance process, which allowed devices like the ASR to come to market without first undergoing human clinical trials. The FDA also advised doctors to consider metal ion testing in those experiencing symptoms of hip implant failure.***

The majority of DePuy ASR hip replacement lawsuits filed since the recall are pending in a multidistrict litigation underway in U.S. District Court, Northern District of Ohio, where Bernstein Liebhard LLP is actively filing claims. Court documents indicate that the first trial in that litigation will begin this June. (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – MDL 2197).

In addition, hundreds of claims have also been filed in state courts throughout the nation. Last month, a Los Angeles Superior Court jury awarded more than $8 million to a plaintiff in the nation’s first trial of a DePuy ASR lawsuit (Kransky v. DePuy, BC456086, California Superior Court, Los Angeles County). However, a jury in Chicago found for Johnson & Johnson in a second trial that was decided earlier this month. (Strum v. DePuy, 2011-L-9352, Circuit Court of Cook County). According to a report from The New York Times, documents disclosed in the course of both proceedings indicated that Johnson & Johnson and DePuy knew that the ASR was defective years before the recall was announced in 2010, but did not disclose this information to the public or the medical community.**

Individuals who suffered metallosis, premature device failure or other complications allegedly related to the DePuy ASR hip recall may be entitled to compensation for their medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding DePuy ASR hip replacement lawsuits is avai
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
2. US Drug Watchdog Now Offers To Get A Free Legal Review For All DePuy ASR Recipients Who Received A Letter From Broadspire About Their Recalled DePuy Hip Implant
3. US Drug Watchdog Now Offers To Help All Recipients Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Get To The Best Attorneys Regardless If Their Device Has Failed
4. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Know The Symptoms Of A Failure And Offers To Name The Best Lawyers & Law Firms For Failure Victims
5. US Drug Watchdog Now Offers To Help Every Recipient Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Who Had To Go Through Revision Surgery Get To The Best Lawyers
6. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
7. US Drug Watchdog Now Offers To Help All Recalled DePuy ASR Hip Implant Recipients Get To The Best Attorneys Out Of Fear These Recipients Won't Be Compensated
8. The US Drug Watchdog Now Offers To Help All Recipients Of Recalled DePuy ASR Hip Implant Get To The Best Attorneys Because Time Could Run Out To Get Them Identified
9. US Drug Watchdog Says Its Critical All DePuy Pinnacle Hip Implant Recipients Know The Symptoms Of A Failure And They Offer The Names Of The Best Attorneys For Victims
10. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Get A Blood Test For Elevated Levels Of Cobalt Or Chromium and to Call Them If The Levels Are high
11. US Drug Watchdog Now Urges All DePuy Pinnacle And DePuy Hip Implant Recipients To Call Them For The Names Of The Best Law Firms Before Time Runs Out To Get Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Stoneham, MA (PRWEB) August 27, 2014 ... lockbox payment processing, today announced that it will exhibit ... New York's (IBANYS) 41st annual convention in ... the 9th. , The event will be held at ... number of exciting activities and entertainment options in addition ...
(Date:8/27/2014)... IQ Formulations , a leading manufacturer of ... of the Cystic Fibrosis Foundation. For an entire month ... led by TigerFitness.com in which 5 percent of the ... to the respected nonprofit organization. , Last year, ... Isla, a young girl fighting Cystic Fibrosis. The company ...
(Date:8/27/2014)... Melbourne, Australia (PRWEB) August 27, 2014 ... by erratic climatic conditions and fluctuations in global supply ... over the past five years. The industry derives a ... manufacturers are subject to global market dynamics, with supply ... as Brazil and India. A strong Australian dollar for ...
(Date:8/27/2014)... Beginning in September, K9 Dog Park will ... interactive, fun way for daycare dogs to learn and compete. ... Park Doggy Daycare clients who bring their dogs into the ... will be able to watch their dogs compete through K9 ... in D.O.G. will win prizes as will the trainers who ...
(Date:8/27/2014)... Lake City, Utah (PRWEB) August 27, 2014 ... of Wasatch Indoor Bike Park, Utah’s first indoor mountain bike ... assortment of mountain and park-style bikes in both adult and ... SCOTT Sports, who already operated a distribution warehouse in Ogden, ... to Salt Lake City. , “We are proud to be ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2
... Medicated heart patients might be in danger, study suggests ... boost blood pressure and heart rate and could pose ... Wayne State University researchers. , They found that drinking ... pressure and heart rate in 15 healthy adults, average ...
... controlled, multi-center trial has found that cardiac resynchronization ... during exercise testing, the trial,s primary endpoint, in ... problems that disrupt the heart,s normal rhythm and ... EKG. , The Resynchronization Therapy in Narrow QRS ...
... Nov. 6 ,PharmAthene, Inc. (Amex: PIP ), ... chemical threats, and Medarex, Inc.,(Nasdaq: MEDX ), ... FY 2008 Department of Defense (DoD) appropriations bill ... reimbursement basis to support,ongoing development of Valortim(TM), a ...
... Neurotech Pharmaceuticals, Inc.,a biotechnology company focused on ... diseases, announced today the completion,of enrollment of ... evaluating,NT-501, the Company,s lead product, for the ... (RP) and the dry form of age-related,macular ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three and ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Revenues for the third ... comparable period a year ago. The Company,reported a ...
... - Bioniche Life Sciences,Inc. (TSX: BNC), a research-based, ... Executive,Vice-President, Corporate & Strategic Development, will present at ... in New York City,tomorrow. Mr. Groome will present ... Room of the New York Palace Hotel. ...
Cached Medicine News:Health News:Energy Drinks Could Pose Blood Pressure Risks 2Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 3Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 4Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 5Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 6Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 7Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 2Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2
(Date:8/27/2014)... 27, 2014 ResearchMoz presents this ...  Laparoscopes Market Outlook to 2020. New report, "United States ... on the United States Laparoscopes market . The ... (in units) and average prices (in US dollars) within ... Flexible Tip Video Laparoscopes), Robotic Surgical Systems and Rigid ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new market ... Baby Food Eastern Europe 2014 ... 2014" is a new report by ERC that analyzes ... Eastern Europe , key segments, features & developments, ... examines trends which are currently affecting the industry. Furthermore, ...
(Date:8/27/2014)... 27, 2014 Sihuan Pharmaceutical Holdings Group ... a leading pharmaceutical company with the largest cardio-cerebral ... prescription drug market, today announced the ... subsidiaries (collectively the "Group") for the six months ... Financial HighlightsFor the Six months ended 30 JuneKey ...
Breaking Medicine Technology:United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... in non-responders to previous interferon-based therapy -, ... non- responders, with less frequent ... Annual Meeting of the American Association for the Study of Liver Diseases ... (AASLD) -, ...
... N.C., Nov. 2 /PRNewswire/,-- Fabre-Kramer Pharmaceuticals Inc. (FKP) ... the U.S. Food and Drug Administration (FDA) has ... application for gepirone extended-,release (ER) tablets, submitted for ... The FDA had previously reviewed Phase I through ...
Cached Medicine Technology:Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder 2
... Size: 3.0 x 5.0 x 100 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... 5.5 x 7.5 x 80 mm. ... II line designed by Harvey A. ... a closed cell sponge which is ... with rounded edges to minimize scleral ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
Medicine Products: